Efficacy and potential of phage therapy against multidrug resistantShigellaspp.

Tang, Swee-Seong; Biswas, Sudhangshu Kumar; Tan, Wen; Saha, Ananda Kumar; Leo, Bey-Fen

doi:10.7717/peerj.6225

Cited by 30 publications

(27 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous animal have studies demonstrated that phages are able to survive in experimental animals with dysentery. Despite no reports on significant undesirable reactions during the long history of phage therapy in humans,176 phage treatments still need to overcome admission constraints in the main medical repertoire.…”

Section: Novel Therapeutic Strategies For Shigella Treatmentmentioning

confidence: 99%

Shigella: Antibiotic-Resistance Mechanisms And New Horizons For Treatment

Ranjbar¹,

Farahani²

2019

IDR

131

View full text Add to dashboard Cite

Shigella spp. are a common cause of diarrheal disease and have remained an important pathogen responsible for increased rates of morbidity and mortality caused by dysentery each year around the globe. Antibiotic treatment of Shigella infections plays an essential role in reducing prevalence and death rates of the disease. However, treatment of these infections remains a challenge, due to the global rise in broad-spectrum resistance to many antibiotics. Drug resistance in Shigella spp. can result from many mechanisms, such as decrease in cellular permeability, extrusion of drugs by active efflux pumps, and overexpression of drug-modifying and -inactivating enzymes or target modification by mutation. Therefore, there is an increasing need for identification and evolution of alternative therapeutic strategies presenting innovative avenues against Shigella infections, as well as paying further attention to this infection. The current review focuses on various antibiotic-resistance mechanisms of Shigella spp. with a particular emphasis on epidemiology and new mechanisms of resistance and their acquisition, and also discusses the status of novel strategies for treatment of Shigella infection and vaccine candidates currently under evaluation in preclinical or clinical phases.

show abstract

Section: Novel Therapeutic Strategies For Shigella Treatmentmentioning

confidence: 99%

Shigella: Antibiotic-Resistance Mechanisms And New Horizons For Treatment

Ranjbar¹,

Farahani²

2019

IDR

131

View full text Add to dashboard Cite

show abstract

“…In terms of controlling bacterial food source pollution, some bacteriophage products have been certified by FDA, such as ListShield TM , EcoShield TM , and SalmoFresh TM (Tang et al, 2019). Currently, ShigaShield TM against Shigella is undergoing FDA and USDA reviews for their safety (Soffer et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…However, after antibiotics were discovered and widely used, only Eastern European countries insisted on phage treatment for infections (Nikolich and Filippov, 2020). In the 21st century, phages against MDR Shigella have been widely investigated (Tang et al, 2019;Kortright et al, 2019). Bernasconi et al proved that three commercially available bacteriophage cocktails could suppress Shigella infections in the human intestine (Bernasconi et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Molecular Characteristics of Novel Phage vB_ShiP-A7 Infecting Multidrug-Resistant Shigella flexneri and Escherichia coli, and Its Bactericidal Effect in vitro and in vivo

Zhang

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

In recent years, increasing evidence has shown that bacteriophages (phages) can inhibit infection caused by multidrug-resistant (MDR) bacteria. Here, we isolated a new phage, named vB_ShiP-A7, using MDR Shigella flexneri as the host. vB_ShiP-A7 is a novel member of Podoviridae, with a latency period of approximately 35 min and a burst size of approximately 100 phage particles/cell. The adsorption rate constant of phage vB_ShiP-A7 to its host S. flexneri was 1.405 × 10–8 mL/min. The vB_ShiP-A7 genome is a linear double-stranded DNA composed of 40,058 bp with 177 bp terminal repeats, encoding 43 putative open reading frames. Comparative genomic analysis demonstrated that the genome sequence of vB_ShiP-A7 is closely related to 15 different phages, which can infect different strains. Mass spectrometry analysis revealed that 12 known proteins and 6 hypothetical proteins exist in the particles of phage vB_ShiP-A7. Our results confirmed that the genome of vB_ShiP-A7 is free of lysogen-related genes, bacterial virulence genes, and antibiotic resistance genes. vB_ShiP-A7 can significantly disrupt the growth of some MDR clinical strains of S. flexneri and Escherichia coli in liquid culture and biofilms in vitro. In addition, vB_ShiP-A7 can reduce the load of S. flexneri by approximately 3–10 folds in an infection model of mice. Therefore, vB_ShiP-A7 is a stable novel phage with the potential to treat infections caused by MDR strains of S. flexneri and E. coli.

show abstract

“…Compared to developing new antibiotics, a more desirable strategy is exploring alternative antibacterial agents that are hard to develop resistance. To meet this requirement, scientists have developed bacteriophages, [40][41] quaternary ammonium compounds, [42] and antimicrobial peptides, [43] etc. In recent years, photodynamic therapy (PDT) reagents including both AIEgens and water-soluble CPs have been applied in drug-resistant bacteria killing with the features of minimal invasiveness and side effects, low cytotoxicity and free of drug resistance.…”

Section: Introductionmentioning

confidence: 99%

AIE-Active Poly(phenyleneethynylene)s for Fluorescence and Raman Dual-Modal Imaging and Drug-Resistant Bacteria Killing

liu²,

Liu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Poly(phenyleneethynylene) (PPE) is a widely used functional conjugated polymer with applications ranging from organic optoelectronics and fluorescence sensors to optical imaging and theranostics. However, the fluorescence efficiency of PPE in aggregate states is generally not as good as their solution states, which greatly compromises their performance in fluorescence-related applications. Herein, we design and synthesize a series of PPE derivatives with typical aggregation-induced emission (AIE) properties. In these PPEs, the diethylamino-substituted tetraphenylethene units function as the long-wavelength AIE source and the alkyl side chains serve as the functionalization site. The obtained AIE-active PPEs with large π-conjugation show strong aggregate-state fluorescence, interesting self-assembly behaviors, inherently enhanced alkyne vibrations in the Raman-silent region of cells, and efficient antibacterial activities. The PPE nanoparticles with good cellular uptake capability can clearly and sensitively visualize the tumor region and residual tumors via their fluorescence and Raman signals, respectively, to benefit the precise tumor surgery. After post-functionalization, the obtained PPE-based polyelectrolyte can preferentially image bacteria over mammalian cells and possesses efficient photodynamic killing capability against Gram-positive and drug-resistant bacteria. This work provides a feasible design strategy for developing multifunctional conjugated polymers with multimodal imaging capability as well as photodynamic antimicrobial ability.

show abstract

Efficacy and potential of phage therapy against multidrug resistantShigellaspp.

Cited by 30 publications

References 153 publications

<p><em>Shigella</em>: Antibiotic-Resistance Mechanisms And New Horizons For Treatment</p>

<p><em>Shigella</em>: Antibiotic-Resistance Mechanisms And New Horizons For Treatment</p>

Molecular Characteristics of Novel Phage vB_ShiP-A7 Infecting Multidrug-Resistant Shigella flexneri and Escherichia coli, and Its Bactericidal Effect in vitro and in vivo

AIE-Active Poly(phenyleneethynylene)s for Fluorescence and Raman Dual-Modal Imaging and Drug-Resistant Bacteria Killing

Contact Info

Product

Resources

About